Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
126 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT01514110 | Gastric Cancer RAD001 Study | completed | Phase 1 / Phase 2 | 35 | Chinese University of Hong KongOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT01645930 |
| Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma |
| completed |
| Phase 1 |
| 43 |
| Millennium Pharmaceuticals, Inc.INDUSTRY |
| 3 |
| Nov 8, 2018 |
| clinicaltrials |
| NCT02648425 | Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | completed | Phase 1 | 31 | ASLAN PharmaceuticalsOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 99 | Puma Biotechnology, Inc.INDUSTRY | 6 | Sep 26, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT00920192 | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | completed | Phase 1 | 45 | GlaxoSmithKlineINDUSTRY | 3 | Jul 18, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01897038 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01251458 | Hepatocellular Carcinoma (HCC)_Torisel_ | completed | Phase 1 / Phase 2 | 46 | Chinese University of Hong KongOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT01096030 | Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | completed | Phase 1 | 33 | BayerINDUSTRY | 2 | Nov 19, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00999882 | Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients | completed | Phase 1 | 26 | AstraZenecaINDUSTRY | 2 | Jul 10, 2012 | clinicaltrials |
| NCT00988195 | Study of Pegylated Human Recombinant Arginase for Liver Cancer | completed | Phase 1 | 15 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT01092091 | Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)(BCT-100-002) | completed | Phase 1 / Phase 2 | 20 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT01256853 | Modified Vaccinia Ankara (MVA) Vaccine Study | completed | Phase 1 | 18 | Chinese University of Hong KongOTHER | 1 | Dec 22, 2011 | clinicaltrials |
| NCT00073736 | Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Ligand PharmaceuticalsINDUSTRY | 3 | Aug 12, 2011 | clinicaltrials |
| NCT00122876 | Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 25 | Light Sciences OncologyINDUSTRY | 3 | Dec 7, 2007 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials